Navigation Links
'Super' enzyme may lead way to better tumor vaccines

A "super" form of the enzyme Akt1 could provide the key to boosting the effect of tumor vaccines by extending the lives of dendritic cells, the immune-system master switches that promote the response of T-cells, which attack tumors, said researchers at Baylor College of Medicine in a report that appears in the "advance online publication" section of the current issue of the journal Nature Biotechnology.

"By keeping the dendritic cells alive longer, you extend the window of activation, promoting the desirable immune response, which in the case of cancer, is the expansion of T-cells," said Dr. David Spencer, associate professor of immunology at BCM. "The longer your dendritic cells are alive and active, the more likely you are to expand the appropriate T-helper repertoire and ultimately the desirable cytotoxic (cell killing) T-lymphocytes."

"The dendritic cells are the master switch in the immune system. They decide whether there will be a robust immune response or a tempered immune response to pathogens or cancer," he said.

Using a variety of sophisticated laboratory techniques, Spencer and his colleagues found that Akt1 "was in fact essential for dendritic cell survival," he said. Then they sought to develop a more potent form of Akt1 that would enable the dendritic cells to live longer, boosting immune response.

To do that, they altered the enzyme so that it targeted a particular domain on the plasma membrane of the cell where signaling occurred, making the action of Akt1 more specific. They then eliminated a small part of the Akt1 molecule that had a negative or inhibitory effect.

"It turned out that the altered molecule was much more potent," Spencer said. He credited graduate student Dongsu Park with doing much of the work to develop the super form of Akt1.

Using specially designed adenoviruses, he and his colleagues put the modified "super" Akt1 molecule into the dendritic cells.

"As predicted, these dendritic cells lived longer and were more potent, both in the laboratory and in mice," he said. "It led to the elimination of some very aggressive tumors in the mice."

In the laboratory, they found that the "super" Akt1 also has a potent effect on human dendritic cells as well, although it has not been used to treat people yet.

He expects that when the enzyme is used in people, the first target will be prostate cancer ?a long-standing interest of his laboratory. However, he said, it could be modified to attack other tumors as well.


Source:Baylor College of Medicine

Related biology news :

1. Lack of enzyme turns fat cells into fat burners
2. Scientists find missing enzyme for tuberculosis iron scavenging pathway
3. Researchers report new pro-inflammatory role for anti-inflammatory enzyme
4. Purdue researchers use enzyme to clip DNA wires
5. Scientists take aim at virulent bacteria by decoding machinery of key control enzyme
6. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
7. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
8. UCLA researchers identify key enzyme linked to childhood blindness
9. K-State professors discover enzyme responsible for creation of a beetles hard shell
10. Smoking damages key regulatory enzyme in the lung
11. New discovery: If it werent for this enzyme, decomposing pesticide would take millennia
Post Your Comments:

(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology: